| scholarly article | Q13442814 |
| P2093 | author name string | Tomoko Takano | |
| Mirela Maier | |||
| Ruth Sapir-Pichhadze | |||
| P2860 | cites work | Interleukin 2 receptor antagonists for kidney transplant recipients | Q24240492 |
| Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia | Q24634431 | ||
| Aging of the immune system: how much can the adaptive immune system adapt? | Q24655059 | ||
| Improving medication adherence among kidney transplant recipients: Findings from other industries, patient engagement, and behavioral economics-A scoping review | Q26770369 | ||
| Translational research in kidney transplantation and the role of patient engagement | Q26778752 | ||
| Clinical immune-monitoring strategies for predicting infection risk in solid organ transplantation | Q26998832 | ||
| Proteomics and metabolomics in renal transplantation-quo vadis? | Q27024418 | ||
| Toward Personalized Medicine in Renal Transplantation | Q28296476 | ||
| Peer Mentoring: A Culturally Sensitive Approach to End-of-Life Planning for Long-Term Dialysis Patients | Q29040096 | ||
| The major genetic determinants of HIV-1 control affect HLA class I peptide presentation | Q29417018 | ||
| Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond | Q29614697 | ||
| How to routinely collect data on patient-reported outcome and experience measures in renal registries in Europe: an expert consensus meeting | Q30664421 | ||
| Statistical resolution of ambiguous HLA typing data | Q31151639 | ||
| Depression is an important contributor to low medication adherence in hemodialyzed patients and transplant recipients | Q33412340 | ||
| The use of personalized medicine for patient selection for renal transplantation: physicians' views on the clinical and ethical implications | Q33551465 | ||
| Optimizing medication adherence: an ongoing opportunity to improve outcomes after kidney transplantation | Q33944763 | ||
| Adherence in patients in the first year after kidney transplantation and its impact on graft loss and mortality: a cross-sectional and prospective study. | Q51138763 | ||
| Structural aspects of human leukocyte antigen class I epitopes detected by human monoclonal antibodies. | Q51455008 | ||
| Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival. | Q51563025 | ||
| A genome-wide association study identifies variants in the HLA-DP locus associated with chronic hepatitis B in Asians. | Q51732144 | ||
| A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. | Q51749415 | ||
| Class II HLA epitope matching-A strategy to minimize de novo donor-specific antibody development and improve outcomes. | Q51775005 | ||
| Identifying Subphenotypes of Antibody-Mediated Rejection in Kidney Transplants. | Q52890132 | ||
| The Canadian kidney paired donation program: a national program to increase living donor transplantation. | Q53082620 | ||
| Immune monitoring of kidney allografts. | Q53171879 | ||
| Patient and family engagement: a framework for understanding the elements and developing interventions and policies. | Q55056999 | ||
| Urinary Metabolomics for Noninvasive Detection of Borderline and Acute T Cell-Mediated Rejection in Children After Kidney Transplantation | Q57014271 | ||
| Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation | Q57134890 | ||
| Gene–Drug Interaction at the Glucocorticoid Receptor Increases Risk of Squamous Cell Skin Cancer | Q59647045 | ||
| Impact of donor mismatches at individual HLA-A, -B, -C, -DR, and -DQ loci on the development of HLA-specific antibodies in patients listed for repeat renal transplantation | Q60168146 | ||
| Improved Adherence to Tacrolimus Once-Daily Formulation in Renal Recipients | Q61403449 | ||
| HLA-DR and -DQ Eplet Mismatches and Transplant Glomerulopathy: A Nested Case-Control Study | Q63244396 | ||
| High-Resolution HLA Typing for Sensitized Patients: Advances in Medicine and Science Require Us to Challenge Existing Paradigms | Q63244397 | ||
| Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg) | Q74815832 | ||
| CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients | Q80316046 | ||
| Association of methylenetetrahydrofolate reductase polymorphism and the risk of squamous cell carcinoma in renal transplant patients | Q80602954 | ||
| The immune risk profile is associated with age and gender: findings from three Swedish population studies of individuals 20-100 years of age | Q80965616 | ||
| Long-term kinetic of T-lymphocyte subsets in kidney-transplant recipients: influence of anti-T-cell antibodies and association with posttransplant malignancies | Q81600359 | ||
| Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence | Q82496190 | ||
| Baseline donor-specific antibody levels and outcomes in positive crossmatch kidney transplantation | Q82732578 | ||
| De novo DQ donor-specific antibodies are associated with a significant risk of antibody-mediated rejection and transplant glomerulopathy | Q84464302 | ||
| Lack of effect in desensitization with intravenous immunoglobulin and rituximab in highly sensitized patients | Q84596458 | ||
| Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression | Q84752883 | ||
| Elevated urinary CXCL10-to-creatinine ratio is associated with subclinical and clinical rejection in pediatric renal transplantation | Q85311745 | ||
| Virtual crossmatch in kidney transplantation | Q85351871 | ||
| The Synergistic Effect of Class II HLA Epitope-Mismatch and Nonadherence on Acute Rejection and Graft Survival | Q85416788 | ||
| Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab | Q86430331 | ||
| Update of the HLA class I eplet database in the website based registry of antibody-defined HLA epitopes | Q87875320 | ||
| High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients | Q89058565 | ||
| Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome. | Q34192317 | ||
| Alemtuzumab induction therapy in kidney transplantation: a systematic review and meta-analysis. | Q34290459 | ||
| Accommodation: preventing injury in transplantation and disease | Q34315248 | ||
| Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial | Q34373536 | ||
| The TAKE-IT study: aims, design, and methods | Q34538633 | ||
| Patient engagement in research: a systematic review | Q35102862 | ||
| The measurement of satisfaction with healthcare: implications for practice from a systematic review of the literature | Q35202277 | ||
| Randomized trial of immunosuppressive regimens in renal transplantation | Q35210227 | ||
| Patients as partners: a qualitative study of patients' engagement in their health care | Q35345979 | ||
| Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance | Q35682221 | ||
| Frequency and impact of nonadherence to immunosuppressants after renal transplantation: a systematic review | Q35691472 | ||
| Utility of HLA Antibody Testing in Kidney Transplantation | Q35790601 | ||
| Living donor age and kidney allograft half-life: implications for living donor paired exchange programs | Q35917423 | ||
| MAGIC Study: Aims, Design and Methods using SystemCHANGE™ to Improve Immunosuppressive Medication Adherence in Adult Kidney Transplant Recipients | Q36078960 | ||
| Differential immunogenicity of HLA mismatches in clinical transplantation | Q36176626 | ||
| Urinary C-X-C Motif Chemokine 10 Independently Improves the Noninvasive Diagnosis of Antibody-Mediated Kidney Allograft Rejection | Q36223302 | ||
| Prevalence, consequences, and determinants of nonadherence in adult renal transplant patients: a literature review | Q36257235 | ||
| Immune Sensitization and Mortality in Wait-Listed Kidney Transplant Candidates | Q36514884 | ||
| Urine Metabolite Profiles Predictive of Human Kidney Allograft Status | Q36514964 | ||
| Biomarkers and surrogate endpoints in clinical trials | Q36552129 | ||
| cPRA Increases With DQA, DPA, and DPB Unacceptable Antigens in the Canadian cPRA Calculator. | Q36554511 | ||
| Genetic predisposition and renal allograft failure: implication of non-HLA genetic variants | Q36554709 | ||
| Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference | Q36666806 | ||
| Metabolomics: a complementary tool in renal transplantation | Q37133845 | ||
| MicroRNA expression profiles predictive of human renal allograft status | Q37146807 | ||
| Can immune monitoring help to minimize immunosuppression in kidney transplantation? | Q37258707 | ||
| Retransplant candidates have donor-specific antibodies that react with structurally defined HLA-DR,DQ,DP epitopes | Q37300446 | ||
| Histocompatibility methods. | Q37418386 | ||
| Kidney transplantation: the ideal immunosuppression regimen | Q37540751 | ||
| Utilization of an EMR-biorepository to identify the genetic predictors of calcineurin-inhibitor toxicity in heart transplant recipients | Q37582074 | ||
| Multicenter validation of urinary CXCL9 as a risk-stratifying biomarker for kidney transplant injury. | Q37648959 | ||
| Quantification of T-cell proliferation for individualizing immunosuppressive therapy for transplantation patients | Q37658274 | ||
| Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review. | Q37705573 | ||
| A 'biomarker signature' for tolerance in transplantation | Q37780676 | ||
| Antibody-reactive epitope determination with HLAMatchmaker and its clinical applications | Q37853627 | ||
| Desensitization protocols and their outcome | Q37858260 | ||
| Can immune cell function assay identify patients at risk of infection or rejection? A meta-analysis | Q37987320 | ||
| Opportunities for shared decision making in kidney transplantation. | Q38089273 | ||
| Molecular pathogenesis of B-cell posttransplant lymphoproliferative disorder: what do we know so far? | Q38108302 | ||
| Advance care planning for adults with CKD: a systematic integrative review. | Q38179159 | ||
| Kidney paired donation: principles, protocols and programs | Q38258064 | ||
| Research priority setting in kidney disease: a systematic review. | Q38315823 | ||
| Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches | Q38353255 | ||
| Immune biomarkers: the promises and pitfalls of personalized medicine. | Q38392912 | ||
| Developing renal allograft surveillance strategies - urinary biomarkers of cellular rejection. | Q38569092 | ||
| Biomarkers in solid organ transplantation: establishing personalized transplantation medicine | Q39183148 | ||
| Social support and immunosuppressant therapy adherence among adult renal transplant recipients | Q39279669 | ||
| Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States | Q39630797 | ||
| A personal view on systems medicine and the emergence of proactive P4 medicine: predictive, preventive, personalized and participatory | Q40027923 | ||
| Value of Donor-Specific Anti-HLA Antibody Monitoring and Characterization for Risk Stratification of Kidney Allograft Loss | Q40634986 | ||
| The mode of sensitization and its influence on allograft outcomes in highly sensitized kidney transplant recipients | Q40663438 | ||
| HLA-DQ matching in cadaveric renal transplantation | Q40878323 | ||
| Biopsy transcriptome expression profiling to identify kidney transplants at risk of chronic injury: a multicentre, prospective study | Q41035928 | ||
| Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch | Q42214147 | ||
| Polymorphisms in glutathione S-transferases are associated with altered risk of nonmelanoma skin cancer in renal transplant recipients: a preliminary analysis | Q42508856 | ||
| A virtual crossmatch protocol significantly increases access of highly sensitized patients to deceased donor kidney transplantation | Q42607322 | ||
| Analysis of anti-HLA antibodies in sensitized kidney transplant candidates subjected to desensitization with intravenous immunoglobulin and rituximab | Q43873334 | ||
| Time-dependent variability in tacrolimus trough blood levels is a risk factor for late kidney transplant failure | Q44535101 | ||
| Quantifying the risk of incompatible kidney transplantation: a multicenter study. | Q44753304 | ||
| Comparing renal transplant patients' adherence to free cyclosporine and free tacrolimus immunosuppressant therapy | Q45230211 | ||
| Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions | Q45342440 | ||
| Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation | Q45627897 | ||
| Positive cross-match living donor kidney transplantation: longer-term outcomes | Q46134337 | ||
| Complement-binding anti-HLA antibodies and kidney-allograft survival | Q46141053 | ||
| HLA high-resolution typing for sensitized patients: a solution in search of a problem? | Q46153238 | ||
| Validation of statistical imputation of allele-level multilocus phased genotypes from ambiguous HLA assignments | Q46228816 | ||
| The need for reorientation toward cost-effective prediction: comments on 'Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond' by M. J. Pencina et al., Statistics in Medicine (DOI: 10 | Q46355737 | ||
| Human leukocyte antigen antibody-incompatible renal transplantation: excellent medium-term outcomes with negative cytotoxic crossmatch. | Q46505754 | ||
| Infusion of high-dose intravenous immunoglobulin fails to lower the strength of human leukocyte antigen antibodies in highly sensitized patients. | Q47194132 | ||
| Unintended Consequences of the New National Kidney Allocation Policy in the United States. | Q47566438 | ||
| Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation | Q47722275 | ||
| Incremental value of a genetic risk score for the prediction of new vascular events in patients with clinically manifest vascular disease | Q48325746 | ||
| Perceived barriers to adherence among adolescent renal transplant candidates | Q48891973 | ||
| De Novo Donor-Specific Human Leukocyte Antigen Antibody Screening in Kidney Transplant Recipients After the First Year Posttransplantation: A Medical Decision Analysis | Q48955987 | ||
| Optimizing immunosuppressive drug dosing in pediatric renal transplantation. Part of a special series on Paediatric Pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni | Q50169065 | ||
| A genetic risk score of 45 coronary artery disease risk variants associates with increased risk of myocardial infarction in 6041 Danish individuals. | Q50566315 | ||
| Genetic polymorphisms in ABCB1 influence the pharmacodynamics of tacrolimus. | Q50930116 | ||
| Desensitization in HLA-incompatible kidney recipients and survival. | Q51018759 | ||
| HLA epitope based matching for transplantation. | Q51091761 | ||
| Describing the evolution of medication nonadherence from pretransplant until 3 years post-transplant and determining pretransplant medication nonadherence as risk factor for post-transplant nonadherence to immunosuppressives: the Swiss Transplant Co | Q51102037 | ||
| P921 | main subject | kidney transplantation | Q740909 |
| P304 | page(s) | 2054358116688227 | |
| P577 | publication date | 2017-01-23 | |
| P1433 | published in | Canadian journal of kidney health and disease | Q27726098 |
| P1476 | title | Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine | |
| P478 | volume | 4 |
Search more.